Aservo® EquiHaler®wins 2021 Pharmapack Award

  • Boehringer Ingelheim’s Aservo® EquiHaler® wins a Pharmapack Health Product Award in the Animal Health category

  • The Pharmapack Awards celebrate the latest innovations within the drugs, medical devices, health products and veterinary drugs sectors

Ingelheim, Germany, October 20, 2021 – Boehringer Ingelheim, a global leader in animal health, is proud to announce that its Aservo® EquiHaler® received a 2021 Pharmapack Health Product Award in the newly established Animal Health category. The Health Product Awards also include Patient-centric Design and Eco Design categories. In 2020, the product received a Red Dot Award for outstanding product design. Aservo® EquiHaler® is an inhalant therapy licensed for use in horses with severe equine asthma.

Launched in 1997, the Pharmapack Awards celebrate the latest innovations in pharma packaging and drug delivery devices within the drugs, medical devices, health products and veterinary drugs sectors. The Awards recognize innovations that have improved drug efficacy, user safety or reduced the environmental impact. The Jury comprises independent pharmacists, physicians, and experts in patient-centric and sustainable packaging.

“This Award is a great acknowledgement of our overarching goal – to improve the life of animals and subsequently humans. I am pleased to see that this innovative solution, a result of a close collaboration between our animal and human health businesses, got recognized by these prestigious awards,” shares Eric Haaksma, Head of Global Innovation at Boehringer Ingelheim Animal Health.

“What makes our Aservo® EquiHaler® stand out is the ergonomic handle and dosing lever for ease of use handling and the nostril adaptor that fits gently inside the horse’s nostril, allowing for easy inhalation of the medicated mist,” explains Martin Folger, Principal Fellow Expert & Risk Management, Global Innovation, Boehringer Ingelheim. “We submitted this product because it is an industry first in equine medicine; until now, there was no approved inhalant therapy licensed for use in horses with severe equine asthma.”

Prof Phillipe Arnaud, the Chair of the Health Product Awards Jury, comments: “After much discussion we decided to award a special prize for Animal Health to the Aservo® EquiHaler® from Boehringer Ingelheim; the Jury was impressed by the innovative nature of the device. We look forward to seeing user feedback and case studies for this product.”

About Pharmapack 

Launched in 1997, Pharmapack is the European event for Pharmaceutical Packaging, Drug Delivery, Medical Devices and Machinery. Pharmapack started as a biennial conference and exhibition, taking place every other year in Paris, until industry developments demanded a more frequent event to help the industry stay up to date on the latest trends, developments and regulations. In the past 20+ years, the event has grown from a conference with a small table-top exhibition, to an event hosting 411 exhibitors and welcoming 5,290 attendees over 2 days. The Pharmapack Awards take place annually alongside the Pharmapack Europe exhibition and conference and recognize pioneering packaging innovations: 

Boehringer Ingelheim Animal Health

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries. For more information visit

Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.